An active surveillance system of invasive pneumococcal disease (IPD) started on September 2008 in Lombardy, Italy, among children aged less than 60 months and admitted for suspicion of IPD at emergency room of ten hospitals. This study examined the clinical characteristics of children enrolled up to December 2010, that is just before the introduction in this region of voluntary mass vaccination, free of charge, based on the 13-valent pneumococcal conjugate vaccine (PCV13). Two hundred fifty one children were suspected and 20 were confirmed as having IPD, based on isolation of Streptococcus pneumoniae from blood. Thirty-nine percent of children had received pneumococcal vaccination previously, and full vaccination with three doses of hepta-valent vaccine (PCV7) had been administered in 21.4%. Co-morbidity conditions were more frequent in children with confirmed than non-confirmed IPD (10.0% vs. 0.9%). The annual incidence rate of confirmed IPD was 28.6/100,000 (binomial 95% confidence interval, 18.6 to 44.1/100,000). Among confirmed IPD children, 11 exhibited pneumonia with bacteremia, 6 bacteremia without focus, 2 septicemia, 1 meningitis. Seventeen (85%) isolates were identified, and nine serotypes. The overall serotype coverage was 29.4% for PCV7 and 82.3% for PCV13. In non-vaccinated children, the coverage of PCV7 and PCV13 was 41.7% and 75.0%, respecttively. Non-vaccine serotypes 12B, 15C, and 23B were identified. Antibiotic resistance was found in seven children, that is against penicillin (serotype 15C), erythromycin (14, 19A, 19F), tetracycline (15C, 19F), chloramphenicol (23F), and trimethoprim-sulfamethoxazole (23F). Two of these children had received antibiotic therapy (penicillin or azithromycin) during the week before hospital admission. The coverage vaccination rate in Lombardy was relatively low during the surveillance period and serotype distribution widespread. The introduction of PCV13 and a mass vaccination program in young children might impact positively on invasive pneumococcal disease in this surveilled population. Active long-term surveillance of non-vaccine serotypes is required wordwide.
Introduction
Streptococcus pneumoniae (S. pneumoniae) is a leading cause of invasive infection and vaccine-preventable deaths among young children [1] [2] [3] [4] . Decline in invasive pneumococcal disease (IPD) has been observed in countries which introduced the heptavalent pneumococcal conjugate vaccine (PCV7) in their immunization programs [5] [6] , with higher reduction in the US, where also decline in IPD mortality occurred [7] . While pneumococcal serotypes may vary across geographical locations, also resulting in different vaccine coverage [2, 8] , nonvaccine serotype replacement may emerge worldwide [9, 10] . The World Health Organization recommends to monitor actively the effect of pneumococcal vaccination [1] .
In Italy, few local studies have been conducted in the past in children aged less than 60 months [11] [12] [13] [14] [15] . Recently Azzari et al. [16] reported merged national data on Italian children aged 0 -16 years, which however focused on serotype coverage only. The heptavalent pneumococcal conjugate vaccine PCV7 was licensed in Italy in 2001 and progressively introduced since 2003, recommended firstly in at-risk children aged less than 5 years and then planned on different regional vaccination strategies. This setting has contributed to make broad difference in the vaccination coverage across geographi-cal areas. In Lombardy, PCV7 was initially offered to at-risk children free of charge, otherwise available at the private market on voluntary demand with co-payment of about USD65 per dose up to December 2009. Based on the current national plan for vaccinations [17] and regional directives, the pneumococcal conjugate vaccine PCV13 is now offered in Lombardy on voluntary demand and free of charge, and vaccination has been scheduled in infants to be administered at three single doses at 3, 5 -6, and 11 -12 months of age [17] .
Indeed, while Lombardy is a crucial region with around 10,000,000 resident people in 2011, the characteristics of IPD in young children, including the pneumococcal serotype distribution, have been never actively investigated.
The main objective of this study was to describe the clinical characteristics of the invasive pneumococcal disease in young children residing in the North-West Lombardy, Italy, and to determine the serotype distribution of S. pneumoniae occurring just before the introduction of the PCV13, that was licensed in Italy for commercialization on April 30, 2010 .
These data would provide general epidemiological information useful to better examine the traits of invasive pneumococcal disease in young children, and further to help the Health Authorities and industry for hopefully improving immunization strategies.
Methods

Setting
This study is a part of an active surveillance of IPD in young children that started on September 01, 2008, in North-West Lombardy, Italy, also including the municipality of Milan. Cases of suspected IPD were collected from ten hospitals homogeneously located in the area delimited by four Reference Local Health Authorities districts. This study analyzed children enrolled up to December 31, 2010 , that is before of the introduction of a new regular vaccination strategy and implementation of the PCV13 in Lombardy. The scrutinized area comprised at the beginning of the surveillance around 3,500,000 people, including 130,000 children aged less than 60 months, of whom 30,000 (12,000 aged less than 24 months) referenced to the participant hospitals.
Subjects
Children admitted at emergency room of the hospitals were assessed for eligibility. Inclusion criteria were: age at admission 28 days -59 months; being residing in the monitored area; suspicion of IPD, that is any S. pneumoniae clinical syndrome; negative urinalysis for urinary tract infections based on fast urine test; C-reactive protein > 15 mg/L. The additional inclusion criterion and/or body (rectal) temperature ≥ 38˚C was considered in children aged ≤ 36 months, as it may be per se suggestive of IPD within this range of age [18] . The exclusion criterion was refusal of parents or the legal guardian to give written consent. Urinalysis was performed by Aution sticks-10EA (ARKRAY Europe, B.V., Amstelveen, The Netherlands). C-reactive protein was measured by direct immunoturbidimetry (Tina-Quant, Roche Diagnostics, Hoffmann-La Roche Ltd, Basel, Switzerland).
Ethics
The study was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The ethics committee of each hospital approved the study protocol. Written informed consent was obtained from the parents or legal guardian after the study had been fully explained.
Case Definition
A case of confirmed IPD was defined in accordance with the Centers for Disease Control and Prevention (Atlanta, GA, USA) [19, 20] . Definition of specific IPD syndrome was in accordance with the International Classification of Diseases-9 [21] .
Identification of Isolates
Blood samples were taken in children within 24 h of recruitment. Cerebrospinal fluid samples were additionally taken in children with clinical syndrome of sepsis and/or meningitis for confirmation. S. pneumoniae isolates were identified by standardized laboratory procedures. Fresh cultures of isolates on blood agar plates and in Amies medium swab were sent to the central reference laboratory (Milan, Italy) for analysis and stored on beads at -70˚C. Isolates were then confirmed for S. pneumoniae by testing for alpha haemolysis on blood agar, optochin susceptibility and bile solubility.
Serotyping and Antimicrobial Susceptibility
Serotyping was based on Omni serum (Statens Serum Institut, Copenhagen, Denmark) that includes antibodies to all recognized S. pneumoniae serotypes. A suspension of the test organism was prepared in saline solution 0.9% from well isolated colonies grown on sheep blood agar plates for 18 to 24 h in 5% CO 2 at 35˚C. One drop of this suspension was mixed with 1 drop of antiserum and 1 drop of methylene blue and, after incubation at room temperature for 10 min, examined at 1000× magnification. Visible evidence of capsular swelling with Omni serum, i.e., a positive Quellung reaction, was considered positive, and followed by type specific antisera. Antimicrobial susceptibility against penicillin G, ceftriaxone, erythromycin, tetracycline, trimethoprim-sulfamethoxazole, chloramphenicol, levofloxacin, linezolid and vancomycin was performed by the E test method (AB Biodisk, Solana, Sweden) on Mueller-Hinton agar supplemented with 5% defibrinated sheep blood (bioMérieux Italia Spa, Bagno a Ripoli, Italy). The minimal inhibitory concentration was defined in accordance with the Clinical and Laboratory Standards Institute breakpoints [22] . S. pneumoniae ATCC 49619 was used as control strain [22] .
Statistical Analysis
Comparison between independent groups was performed by the Chi-square or Fisher's exact test or Mann-Whitney U test, as appropriate. Significance was posed at P < 0.05 (two-tails). The statistical analyses were done using the SPSS software, version 17.0 for Windows (SPSS Inc., Chicago, IL).
Results
Two hundred fifty one children (140 boys, 111 girls; mean age [SD] 27.5 [16.8] months) were recruited. Blood testing data were available in 236 cases, and 20 (13 boys, 7 girls) were confirmed as having IPD. All of them were hospitalized. No fatality outcome occurred during hospitalization. The pooled annual incidence rate of confirmed IPD was 28.6/100,000 (binomial 95% confidence interval, 18.6 to 44.1/100,000), that is 30.0/100,000 (16.0 to 46.9/100,000) in infants and 26.2/100,000 (14.8 to 48.9/100,000) in children aged 2 -4 years. Table 1 reports the baseline characteristics of children by IPD status. The rate of co-morbidity conditions was higher in children with confirmed than non-confirmed (suspected) IPD. No child was human immunodeficiency virus positive. The overall expected serotype coverage rate, estimated on typified IPD cases, was 29.4% for PCV7 and 82.3% for PCV13. In non-vaccinated children, the coverage of PCV7 and PCV13 was 41.7% and 75.0%, respectively. 
Data are number of cases. Number of children aged < 24 or 24 -59 months within square brackets. Number of cases showing any antibiotic resistance within round brackets, when different from zero. a Not available = 2 non-viable cultures, 1 blood sample damaged.
Discussion
In the monitored area, before the introduction of PCV13, around 25% of confirmed IPD were caused by PCV7 serotypes, a proportion that is comparable with recent data from some European countries (e.g. 17% in Portugal [23] ) but is higher than in the US (around 2 -3% [5, 24] ). As pointed out by Aguiar et al. [23] , a major factor for the difference may be the different vaccination programs adopted across geographical locations. Indeed, in this study 39% of children with suspected IPD had received pneumococcal vaccination, and full vaccination with three doses of PCV7 was administered in 21.4% of children only. While this is a relatively low vaccination rate, it should be noted that a report from the National Department of Health revealed at the time of starting this study difference in PVC7 coverage among different Italian regions, ranging from 20% (Campania, South) to 95.2% (Emilia-Romagna, North), with a value of 27% in Lombardy [25] . The estimated annual incidence of IPD in children aged less than 5 years was 28.6/100,000, that is similar to what has been reported in previuos Italian studies [11-14, and also comparable with data from the Active Bacterial Core Surveillance, an active population-and laboratorybased surveillance system in US, that estimated in 2010 an incidence of about 25 cases per 100,000 in the population aged 0 -4 years [26] . In Lombardy, the new strategy adopted on July 2010 about voluntary mass pneumococcal vaccination offered free of charge in all children, and availability of PCV13, may be expected to impact positively on the coverage pneumococcal vaccination and IPD in young children. This active surveillance will provide in few years additional valuable data to appraise accurately effectiveness of this recent vaccine.
Regarding the serotype distribution, serotypes 7F and 19A caused the majority of IPD, as also observed in the US [5, 24] [28] . The relevance of this serotype, included in PCV13 but not in PCV7, has been as well indicated in South-West Asian countries [e.g., 29], and emphasized recently [30, 31] .
Based on the results, the expected overall serotype coverage of PCV13 (82.3%) would be within the range of values reported in the literature ( [10, 23] ). Recently, Azzari et al. [16] estimated in Italy a national pooled serotype coverage of 19.4% and 94% for PCV7 and PCV13, respectively. However, it should be noted that in the present study, heterogeneity in the serotype distribution of IPD was found, with a proportion of around 15% of serotypes not included in any pneumococcal vaccine, as also observed recently in Aguiar et al. [23] .
Concerning antimicrobial susceptibility, while the PCV7 serotypes accounted for the majority of erythromycin resistant isolates, consistently with recent literature [23] , the only penicillin resistant serotype was 15C. Moreover, it may be interestingly noted that two of the seven children who had received antibiotic therapy during the week before hospital admission exhibited serotype 19F and 23F both resistant against erythromycin.
Lastly, it may be of interest to point out that, in this study, baseline clinical conditions at hospital admission did not significantly differ between children with confirmed and non confirmed (suspected) IPD, except for presence of higher co-morbidity in confirmed IPD cases. Moreover, rectal temperature ad hospital admission was 38˚C or higher in about 85% of children. Although this result may be not unexpected it supports about value of the US approach to perform blood culture for every febrile young child.
This study has the major limitation of the small sample size of IPD cases, when compared with a recent report examining 144 pediatric hospitalized cases with IPD and identified serotype from 83 centers in 19 of 20 Italian regions [16] . Crudely, it may seem therefore of limited novelty, reporting data that may be not unexpected. However, it should be noted that in their study, Azzari et al. [16] included from Lombardy even fewer cases. Another limitation is that real-time-PCR analysis was not performed. Indeed, while use of molecular-based methods for the diagnosis of bacterial infections in blood is appealing and useful in research, real-time-PCR with blood samples for diagnosis of IPD may lack the sensitivity and specificity necessary for clinical practice [32] . Anyway, this study may have some strengths that might make it interesting and unique. Firstly, it is the only active surveillance of IPD implemented in Lombardy, that additionally evaluated the status of IPD up to the introduction of PCV13 in a European geographic region of high population density, for which few data exist. These data may therefore report useful information to the international scientific community, health authorities and industry for improving immunization pneumococcal strategies. Secondly, it would give a basis for a subsequent meaningful analysis about the impact of PCV13 and potential serotype replacement process.
Conclusion
As a whole, within the limitations of this study, one can conclude that PCV13 mass vaccination in Lombardy young children could positively impact on IPD. The dynamical role of non-vaccine S. pneumoniae serotypes, that might potentially limit the vaccines effectiveness, should be monitored through long-term active surveillance, hopefully coordinated across international countries.
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